CLLS
Cellectis
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CLLS Profile
Cellectis S.A.
A biotechnology company that develops immunotherapies and gene-edited allogenic cancer therapies
Biological Technology
01/04/2000
03/25/2015
NASDAQ Stock Exchange
222
12-31
Depository Receipts (Ordinary Shares)
8, rue de la Croix Jarry, 75013 Paris, France
--
Cellectis S.A. was established on January 4, 2000. The company is a clinical-stage biotechnology company that leverages their core proprietary technology to develop gene-edited products with a portfolio of allogeneic chimeric antigen receptor T cells, or candidates in the field of immuno-oncology, and gene-edited hematopoietic stem cells and progenitors, or HSPC, candidates for other therapeutic indications.